Trial Profile

A Phase 2a Crossover Trial Evaluating the Safety of and Adherence to a Vaginal Matrix Ring Containing Dapivirine and Oral Emtricitabine/Tenofovir Disoproxil Fumarate in an Adolescent and Young Adult Female Population

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dapivirine (Primary) ; Emtricitabine/tenofovir disoproxil fumarate (Primary)
Indications HIV infections
Focus Adverse reactions; Pharmacokinetics
Acronyms REACH

16 Feb 2022 Results assessing choice of and adherence to the ring and oral PrEP among African AGYW presented at the 29th Conference on Retroviruses and Opportunistic Infections
02 Nov 2021 Status changed from active, no longer recruiting to completed.
21 Jul 2021 Interim results reporting safety, adherence and acceptability of both products presented at the 11th International AIDS Society Conference on HIV Science

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com